key: cord-0861784-cc23zega
authors: Murai, I. H.; Fernandes, A. L.; Sales, L. P.; Pinto, A. J.; Goessler, K. F.; Duran, C. S. C.; Silva, C. B. R.; Franco, A. S.; Macedo, M. B.; Dalmolin, H. H. H.; Baggio, J.; Balbi, G. G. M.; Reis, B. Z.; Antonangelo, L.; Caparbo, V. F.; Gualano, B.; Pereira, R. M. R.
title: Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized Controlled Trial.
date: 2020-11-17
journal: nan
DOI: 10.1101/2020.11.16.20232397
sha: 1f04ad116941b50410ae49d4d403108be1de0288
doc_id: 861784
cord_uid: cc23zega

Importance: Patients with COVID-19 may exhibit 25-hydroxyvitamin D deficiency, but the beneficial effects of vitamin D3 supplementation in this disease remain to be proven by randomized controlled trials. Objective: To investigate the efficacy and safety of vitamin D3 supplementation in patients with severe COVID-19. Design, Setting, and Participants: This is a multicenter, double-blind, randomized, placebo-controlled trial conducted in two centers (a quaternary hospital and a field hospital) in Sao Paulo, Brazil. The trial included 240 hospitalized patients with severe COVID-19. The study was conducted from June 2, 2020 to October 7, 2020. Interventions: Patients were randomly allocated (1:1 ratio) to receive either a single oral dose of 200,000 IU of vitamin D3 or placebo. Main Outcomes and Measures: The primary outcome was hospital length of stay, defined as hospital discharge from the date of randomization or death. Secondary outcomes were mortality, admission to ICU, mechanical ventilation requirement, and serum levels of 25-hydroxyvitamin D, creatinine, calcium, C-reactive protein, and D-dimer. Results: Of 240 randomized patients (mean age, 56 years; 56% men), 232 (96.7%) were included in the primary analysis. Log-rank test showed that hospital length of stay was comparable between the vitamin D3 supplementation and placebo groups (7.0 days [95% CI, 6.1 to 7.9] and 7.0 days [95% CI, 6.2 to 7.8 days]; hazard ratio, 1.12 [95% CI, 0.9 to 1.5]; P = .379; respectively). The rate of mortality (7.0% vs 5.1%; P = .590), admission to ICU (15.8% vs 21.2%; P = .314), and mechanical ventilation requirement (7.0% vs 14.4%; P = .090) did not significantly differ between groups. Vitamin D3 supplementation significantly increased serum 25-hydroxyvitamin D levels compared to placebo (difference, 24.0 ng/mL [95% CI, 21.0% to 26.9%]; P = .001). No adverse events were observed. Conclusions and Relevance: Among hospitalized patients with severe COVID-19, vitamin D3 supplementation was safe and increased 25-hydroxyvitamin D levels, but did not reduce hospital length of stay or any other relevant outcomes vs placebo. This trial does not support the use of vitamin D3 supplementation as an adjuvant treatment of patients with COVID-19.

A growing body of evidence has indicated that vitamin D may enhance the innate 1-3 and 2 adaptive immunity. 4, 5 Since antigen-presenting cells have the ability to synthesize 1,25-3 dihydroxyvitamin D (the active form of vitamin D) from 25-hydroxyvitamin D, it has 4 been postulated that vitamin D supplementation could improve the function of 5 macrophages and dendritic cells, thereby ameliorating overall immune response. 6 In 6 fact, insufficient vitamin D status has been suggested as a potential risk factor for non-7 communicable 7 and acute respiratory tract diseases, 8, 9 including viral infections. 10 8 In this context, it has been recently conjectured that optimal levels of vitamin D could 9 play important immunomodulatory and anti-inflammatory roles, thereby benefiting 10 patients with COVID-19. 11, 12 However, the putative benefits of supplementary vitamin 11 D3 to patients with COVID-19 remain speculative and partially supported by limited 12 data from observational studies and one small-scale, non-randomized clinical trial. 13-15 13 To our knowledge, this is the first randomized, double-blind, placebo-controlled trial to is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11. 16.20232397 doi: medRxiv preprint mellitus, systemic arterial hypertension, neoplasms, immunosuppression, pulmonary 1 tuberculosis, and obesity, followed by COVID-19 confirmation before randomization. 2 3

Exclusion criteria were: 1) patient unable to read and sign the written informed consent; 5

2) patient already admitted under invasive mechanical ventilation; 3) previous vitamin 6 D3 supplementation (> 1000 IU/day); 4) renal failure requiring dialysis or creatinine ≥ 7 2.0 mg/dL; 5) hypercalcemia defined by total calcium > 10.5 mg/dL; 6) pregnant or 8 lactating women; and 7) patients with expected hospital discharge in less than 24 hours. 9

10

This was a multicenter, double-blind, parallel-group, randomized placebo-controlled 12 trial. Eligibility screening was performed between June 2, 2020 to July 21, 2020 at 13

Clinical Hospital of the School of Medicine of the University of Sao Paulo (n = 122), 14 and from July 22, 2020 to August 27, 2020 at Ibirapuera Field Hospital (n = 118). The 15

final follow-up in both centers was on October 7, 2020. Eligible patients were assigned 16 in a 1:1 ratio into either the vitamin D3 supplementation group or the placebo group. 17

The randomization list was created using a computer-generated code, which was 18 managed by a staff member who had no role in the study. We assessed patients' clinical 19 status, coexisting chronic diseases, demographic characteristics, self-reported body 20 weight and height, and ethnicity on hospital admission. Outcomes were assessed at 21 baseline and on hospital discharge or death records. 22

The vitamin D3 supplementation group received an oral, single dose of 200,000 IU of 23 vitamin D3 dissolved in a 10 mL of peanut oil solution on the same day of 24 randomization. The selected dose is within the recommended range for effectively 25 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint promoting vitamin D sufficiency. 16 Patients in the placebo group received 10 mL of 1 peanut oil solution. The vitamin D3 and placebo solutions were identical in color, taste, 2 smell, consistency, and container. Both were prepared by the pharmacy unit of Clinical 3

Hospital and labeled by a staff member who did not participate in the study. Allocation 4 blindness was kept until the final statistical analysis. 5 6

The primary outcome was hospital length of stay, defined as the total number of days 8 that patients remained hospitalized from the date of study admission until the date of 9

hospital discharge or death. The criteria used for patient discharge were: 1) no need for 10 supplemental oxygen in the last 48 hours; 2) no fever in the last 72 hours; and 3) 11 oxygen saturation > 93% in room air without respiratory distress. 12

The secondary outcomes were: 1) mortality; 2) number of patients admitted to the 13 intensive care unit (ICU); 3) number of patients who needed mechanical ventilation and 14 duration of mechanical ventilation; and 4) serum levels of 25-hydroxyvitamin D 15

(assessed by a chemiluminescent immunoassay), calcium (assessed by a NM-BAPTA 16 method), creatinine (assessed by a colorimetric assay based on kinetic Jaffe's reaction), 17 and C-reactive protein and D-dimer (both assessed by an immunoturbidimetric assay). 18

The biochemical analyses were carried out in an accredited laboratory from Clinical 19

Hospital. 20 21

Considering the lack of data available for sample size determination based on the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint feasibility, such as resources, capacity of research staff and facility, and available 1 patients, in line with current recommendations. 17, 18 Subsequently, we calculated sample 2 size assuming a 50% between-group difference in hospital length of stay (considering 7 3 days as a median time of stay, with an expected variability of 9 days). By considering a 4 power of 80% and a 2-sided significance level of 5% (α = .05), the total sample was 5 estimated to be 208 patients (104 in each arm). Considering possible dropouts, and to 6 increase the power for secondary outcomes, we opted by increasing the sample size by 7 approximately 15%. 8

All analyses were carried out following the intention-to-treat principle for all 9 randomized patients, with no imputation for any missing data. Proportions were 10 compared between groups using c 2 test and Fisher's exact test. Student's t-tests were 11 used for comparing continuous variables at baseline. The log-rank test was used to 12 compare the Kaplan-Meier estimate curves the number of days for hospital length of 13 stay, the primary outcome. Cox regression models for hospital length of stay, admission 14 to ICU and mechanical ventilation requirement were adjusted by potential confounders 15 that were not fully balanced by randomization (P < .2) to estimate hazard ratios (HR), is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11. 16.20232397 doi: medRxiv preprint Statistical analyses were performed with IBM-SPSS software, version 20.0. 1

Significance level was set at α = .05. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020.

Of 1208 patients assessed for eligibility, 240 were eligible and randomly assigned to 3 either the vitamin D3 group or the placebo group. Patients were non-eligible due to the 4 following reasons: 284 were at ICU, 263 had hospital discharge within 24 hours, 217 5 did not have COVID-19 confirmation, 95 had renal dysfunction, 37 had dementia or 6

severe mental confusion hampering their ability to provide the inform consent for 7 participation, 30 were pregnant or lactating women, 14 had hypercalcemia due to 8 metastatic neoplasm, 11 were receiving vitamin D3 (≥ 1000 IU/day), 9 were younger 9 than 18 years, 6 were illiterate and, therefore, unable to read and sign the informed 10 consent, and 2 died before randomization. 11

Of the 120 patients who were randomized to the vitamin D3 group, 3 did not receive 12 intervention (1 withdrew the consent, 1 vomited immediately after ingesting the 13 supplement, and 1 was admitted to the ICU before taking vitamin D3) and 3 were lost to 14 follow-up. Of the 120 patients who were randomized to the placebo group, 2 withdrew 15 the consent. Thus, of the 240 patients randomized, 232 (96.7%) completed the follow-16 up (Figure 1 ). 17

Overall, patients' age was 56.3 years (SD, 14.6), BMI was 31.6 kg/m 2 (SD, 7.1), 56.3% 18 were men, 55% were white, 52.5% had hypertension, 35% had diabetes, 13.3% had 19 cardiovascular diseases, and 6.3% had asthma. The mean time between the onset of 20 symptoms and randomization was 10.2 days (SD, 4.3); 89.6% required supplemental 21 oxygen at baseline (183 were on oxygen therapy and 32 were on non-invasive 22 ventilation), and 59.6% had computed tomography scan findings suggestive of COVID-23

19. Demographic and clinical characteristics did not significantly differ between groups, 24 except for sore throat, which was more prevalent in the vitamin D3 group vs placebo 25 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint (38.3% vs 24.2%, P = .026), and PTH, which was higher in the vitamin D3 group vs 1 placebo (50.1 vs 42.6 pg/mL, P = .025) ( Table 1) . 2 3

Hospital length of stay ( Figure 2 ) was comparable between the vitamin D3 group and 5 the placebo group (7.0 days [95% CI, 6.1 to 7.9] and 7.0 days [95% CI, 6.2 to 7.8 days], 6 HR, 1.12, [95% CI, 0.9 to 1.5]; P = .379; respectively). The Cox regression model did 7 not show any significant associations between this outcome and potential confounders. 8 9

There were no significant differences between the vitamin D3 group and the placebo 11 group for mortality (7.0% vs 5.1%; P = .590), admission to ICU (15.8% vs 21.2%; P = 12 .314) and mechanical ventilation requirement (7.0% vs 14.4%; P = .090) (Figure 3) . 13

Duration of mechanical ventilation was also comparable between the vitamin D3 group 14 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (Figure 3) . Among the patients with 25-hydroxyvitamin D 5 deficiency, no between-group differences were observed in length of hospital stay 6 ( Figure 2 ). In addition, there were no significant differences between the vitamin D3 7 group and the placebo group for mortality (7.0% vs 1.7%; P = .206), admission to ICU 8 (17.5% vs 15.5%; P = .806), and mechanical ventilation requirement (7.0% vs 8.6%; P 9 > .999) (Figure 3) . Duration of mechanical ventilation did not differ between the 

There were no changes in any health-related laboratory markers following the 15 intervention ( Table 2) . Vitamin D3 supplementation was well tolerated and no severe 16 adverse events were reported throughout the trial, with the exception of one patient who 17 vomited following vitamin D3 administration. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint Vitamin D has been postulated to play an important role on immune system, acting as a 1 regulator of both innate and adaptative responses. 6, 19 Observational studies have shown 2 that 25-hydroxyvitamin D levels are associated with better clinical outcomes in 3 respiratory diseases. 20 Positive associations between low 25-hydroxyvitamin D levels 4

and poor prognosis among patients with COVID-19 have also been observed. 21 5

Furthermore, a small-scale, non-randomized trial demonstrated that the administration 6 of regular boluses of vitamin D3 before the infection was associated with better survival 7 and less severe disease among older, frail patients with COVID-19. 22 In the current trial, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint parameters, suggesting that a relatively high-dose of vitamin D3 can be well tolerated in 1 general and free of adverse effects in patients with COVID-19. 2

The strengths of this study include the randomized, double-blind, placebo-controlled 3 experimental design, the adequate power, particularly for the primary analysis, the very 4 low attrition rate (3.3%), the concomitant assessment of 25-hydroxyvitamin D levels 5 along with clinical outcomes, and the assessment of hospitalized patients with severe 6 COVID-19. 7 8

This trial has several limitations. First, the sample size could have been underpowered 10 to detect significant changes for the secondary outcomes. Second, as the patients had 11 several coexisting diseases and were subjected to a diverse medication regimen, the 12 results could have been affected by the heterogeneity of the sample and its treatment. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint all the staff members from both centers; all the patients who participated in this study. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint [95% CI, 19.3-26.1]; P < .001). Box plots depict median and interquartile range. Outliers (i.e., defined as a value < 5 or > 95 percentiles) were represented by filled circles. * means P < .05 between Baseline and Post; # means P < .05 between groups at Post. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11. 16 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11. 16 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11. 16 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 17, 2020. ; https://doi.org/10.1101/2020.11.16.20232397 doi: medRxiv preprint

Toll-like receptor triggering of a vitamin Dmediated human antimicrobial response

Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children

Autophagy induction by vitamin D inhibits both Mycobacterium tuberculosis and human immunodeficiency virus type 1

Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts

Vitamin D Receptor polymorphisms and risk of enveloped virus infection: A meta-analysis

MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19

Vitamin D status and ill health: a systematic review

Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individualparticipant data meta-analysis

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

Vitamin-D and COVID-19: do deficient risk a poorer outcome?

Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrinol

Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results

SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels

The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality

Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review

Current sample size conventions: flaws, harms, and alternatives

Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: A systematic review and meta-analysis. Medicine (Baltimore)

Epidemic influenza and vitamin D

Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study

Vitamin D Status in Hospitalized Patients With SARS-CoV-2 Infection